• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Demonstration of specific dopamine receptors on human pituitary adenomas.

作者信息

Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, Kishimoto S, Mori S, Uozumi T

出版信息

Acta Endocrinol (Copenh). 1987 Apr;114(4):595-602. doi: 10.1530/acta.0.1140595.

DOI:10.1530/acta.0.1140595
PMID:3577589
Abstract

Dopamine receptors on human pituitary adenoma membranes were characterized using [3H] spiperone as the radioligand. The specific [3H]spiperone binding sites on prolactin (PRL)-secreting adenoma membranes were recognized as a dopamine receptor, based upon the data showing high affinity binding, saturability, specificity, temperature dependence, and reversibility. All of 14 PRL-secreting adenomas had high affinity dopamine receptors, with a dissociation constant (Kd) of 0.85 +/- 0.11 nmol/l (mean +/- SEM) and a maximal binding capacity (Bmax) of 428 +/- 48.6 fmol/mg protein. Among 14 growth hormone (GH)-secreting adenomas examined, 8 (57%) had dopamine receptors with a Kd of 1.90 +/- 0.47 nmol/l and a Bmax of 131 +/- 36.9 fmol/mg protein. Furthermore, 15 of 24 (58%) nonsecreting pituitary adenomas also had dopamine receptors with a Kd of 1.86 +/- 0.37 nmol/l and a Bmax of 162 +/- 26.0 fmol/mg protein. These results indicate that some GH-secreting adenomas as well as some nonsecreting pituitary adenomas contain dopamine receptors. But their affinity and number of binding sites are significantly lower (P less than 0.05) and fewer (P less than 0.001) respectively, than those in PRL-secreting adenomas.

摘要

相似文献

1
Demonstration of specific dopamine receptors on human pituitary adenomas.
Acta Endocrinol (Copenh). 1987 Apr;114(4):595-602. doi: 10.1530/acta.0.1140595.
2
Dopaminergic binding sites in human pituitary adenomas other than prolactinomas.除催乳素瘤外的人类垂体腺瘤中的多巴胺能结合位点。
Horm Res. 1984;19(2):97-102. doi: 10.1159/000179873.
3
Dopamine receptors in immunohistochemically characterized null cell adenomas and normal human pituitaries.免疫组织化学鉴定的无功能细胞腺瘤和正常人体垂体中的多巴胺受体。
Mod Pathol. 1988 Jan;1(1):51-6.
4
Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system.人生长激素(GH)分泌性腺瘤中多巴胺受体的证据以及在灌注系统中多巴胺对GH分泌抑制作用的同步研究。
J Clin Endocrinol Metab. 1982 Sep;55(3):589-93. doi: 10.1210/jcem-55-3-589.
5
Resistance to bromocriptine in prolactinomas.催乳素瘤对溴隐亭的耐药性。
J Clin Endocrinol Metab. 1989 Sep;69(3):500-9. doi: 10.1210/jcem-69-3-500.
6
Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine.无功能垂体腺瘤在溴隐亭治疗期间不会消退,但具有可结合溴隐亭的膜结合多巴胺受体。
Clin Endocrinol (Oxf). 1986 Nov;25(5):561-72. doi: 10.1111/j.1365-2265.1986.tb03610.x.
7
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.组织激肽释放酶与人生长激素分泌性腺瘤内的催乳素分泌细胞相关。
J Endocrinol. 1992 Jul;134(1):149-54. doi: 10.1677/joe.0.1340149.
8
Specific somatostatin receptors on human pituitary adenoma cell membranes.人垂体腺瘤细胞膜上的特异性生长抑素受体。
J Clin Endocrinol Metab. 1985 Oct;61(4):666-71. doi: 10.1210/jcem-61-4-666.
9
Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.
J Clin Endocrinol Metab. 1980 Nov;51(5):1037-44. doi: 10.1210/jcem-51-5-1037.
10
Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.人生长激素-催乳素分泌型垂体腺瘤细胞培养中的激素分泌:溴隐亭的作用
J Tongji Med Univ. 1998;18(3):161-3. doi: 10.1007/BF02888527.

引用本文的文献

1
Effects of Dopamine on stem cells and its potential roles in the treatment of inflammatory disorders: a narrative review.多巴胺对干细胞的影响及其在治疗炎症性疾病中的潜在作用:叙述性综述。
Stem Cell Res Ther. 2023 Aug 30;14(1):230. doi: 10.1186/s13287-023-03454-w.
2
Dopamine Agonists for Pituitary Adenomas.用于垂体腺瘤的多巴胺激动剂
Front Endocrinol (Lausanne). 2018 Aug 21;9:469. doi: 10.3389/fendo.2018.00469. eCollection 2018.
3
11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.11C-蛋氨酸PET用于复发性垂体腺瘤的诊断与管理。
Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):169-78. doi: 10.1007/s00259-005-1882-0. Epub 2005 Oct 15.
4
Endocrine inactive and gonadotroph adenomas: diagnosis and management.内分泌无活性及促性腺激素腺瘤:诊断与管理
J Neurooncol. 2001 Sep;54(2):167-77. doi: 10.1023/a:1012965617685.
5
Dopamine D2 receptor gene expression in human adenohypophysial adenomas.人腺垂体腺瘤中多巴胺D2受体基因的表达
Endocrine. 2001 Apr;14(3):329-36. doi: 10.1385/endo:14:3:329.
6
The role of hormones, growth factors and their receptors in pituitary tumorigenesis.激素、生长因子及其受体在垂体肿瘤发生中的作用。
Brain Pathol. 2001 Jul;11(3):356-70. doi: 10.1111/j.1750-3639.2001.tb00405.x.
7
Receptor imaging in the diagnosis and treatment of pituitary tumors.垂体瘤诊断与治疗中的受体显像
J Endocrinol Invest. 1999 Jan;22(1):80-8. doi: 10.1007/BF03345484.
8
Differentiation of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography with [18F]fluoro-ethyl-spiperone.利用[18F]氟乙基螺哌隆正电子发射断层扫描技术鉴别临床无功能垂体腺瘤与脑膜瘤及颅咽管瘤
Eur J Nucl Med. 1997 Sep;24(9):1149-55. doi: 10.1007/BF01254248.
9
Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.多巴胺激动剂药物对分泌催乳素的垂体腺瘤的影响。一项包括免疫细胞化学、电子显微镜检查和原位杂交的形态学研究。
Virchows Arch A Pathol Anat Histopathol. 1991;418(5):439-46. doi: 10.1007/BF01605931.
10
Positron emission tomography applied in the study of pituitary adenomas.正电子发射断层扫描在垂体腺瘤研究中的应用。
J Endocrinol Invest. 1991 Jun;14(6):509-28. doi: 10.1007/BF03346855.